In the present systematic review and meta-analysis, we aimed to assess and highlight the most important polymorphic pharmacogenetic markers of the CYP3A4 gene associated with prostatic neoplasia, particularly with prostate cancer risk in European Caucasians. The gene discussed is CYP3A4; the disease is Familial prostate cancer.